← Back to Search

Monoclonal Antibodies

Bevacizumab for Cancer

Phase 1
Waitlist Available
Led By Filip Janku, MD,PHD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days after the last dose of study drugs
Awards & highlights

Study Summary

This trial is testing a combination of drugs to see what dose is tolerable for patients with advanced cancer, as well as studying the safety of the drug combination.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days after the last dose of study drugs
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days after the last dose of study drugs for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD) of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment
Secondary outcome measures
Antitumor Efficacy of the Combination of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dasatinib, Bevacizumab + PaclitaxelExperimental Treatment3 Interventions
Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15 Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280
Dasatinib
2012
Completed Phase 3
~2320
Paclitaxel
2011
Completed Phase 4
~5380

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,974 Previous Clinical Trials
1,789,274 Total Patients Enrolled
Filip Janku, MD,PHDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
165 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
2009. "Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01015222.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top